Buying generic medicine

We've done some research and found two inexpenisve sources of PrEP online.

 

Tenvir EM 300/200

MANUFACTURED BY CIPLA  $271 AUD, 90 pills - including delivery

 

Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, that primarily develops medicines to treat cardiovascular disease, arthritis, diabetes, weight control and depression; and other medical conditions. As of 17 September 2014, its market capitalisation was US$7.8 billion,Cipla has been manufacturing Tenvir EM 300/200 as a generic for Truvada since 2010. Today, it is one of the world’s largest generic pharmaceutical companies with a strong presence in over 170 countries. Cipla employs a worldwide staff of 20 000.

 

Adco Emtevir

MANUFACTURED BY ADCOCK INGRAM   $160 AUD, 90 pills - including delivery

 

Adcock Ingram Limited first started out as a pharmacy in South Africa 125 years ago. Beginning with this one small pharmacy, Adcock Ingram was first listed on the Johannesburg Stock Exchange in 1950. It is now the second largest Pharmaceutical company in South Africa. Adcock Ingram manufactures and markets a wide range of healthcare products. The company is a leading supplier to both the private and public sectors of the market and has been manufacturing Antiretroviral generics since 2005. Its market capitalisation is about US$6.5 billion. Adcock Ingram released Adco Emtevir as a licenced generic for Truvada to the market in December 2011. It has 4000 employees and operates both in South Africa and India.

 

Generics are as good

Both Tenvir EM 300/200 & Adco Emtevir contain exactly the same ingredients that are present in the original PrEP drug Truvada.  Both Cipla & Adcock Ingram have been licenced to manufacture their generics by Gilead the manufacturer of Truvada. These licencing agreements provide for ongoing regulating of quality control.  In order for each company to have their generic product registered they would have had to comply with a

NON INFERIOR ASSESSMENT TRIAL :

 

• New treatments that are potentially as effective as existing treatments are increasingly being developed, some of which may be preferred because of lower cost, fewer side effects, easier administration or less harm.

• Non-inferiority trials attempt to establish whether or not a new treatment — drug or non-drug — is no worse than an established treatment for which efficacy has been determined in placebo-controlled trials.

• Critical issues in the design and conduct of non-inferiority trials include:

  • defining the acceptable margin of adverse events that, if exceeded, will render the new treatment inferior to the standard treatment (the non-inferiority margin);

  • calculating the sample size needed to demonstrate non-inferiority;

  • assessing the robustness of results in terms of absolute versus relative effects, intention-to-treat versus per-protocol analyses, one-sided versus two-sided statistical tests, and observed versus expected event rates for standard treatment;

  • evaluating all relevant outcomes, including harm; and

  • stating conclusions that are consistent with aims and results.